Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids.

Abstract

Targeting the nuclear factor kappa B (NFκB) pathway is proposed as therapy for chronic lymphocytic leukemia (CLL). We hypothesized that an omega-3 fatty acids (n-3) supplement would suppress NFκB activation in lymphocytes of Rai Stage 0-1 CLL patients. The initial dose of 2.4 g n-3/day was gradually increased to 7.2 g n-3/day. After n-3 consumption: 1) plasma n-3 increased; 2) NFκB activation was suppressed in lymphocytes; 3) in vitro sensitivity of lymphocytes to doxorubicin was increased; and 4) expression of 32 genes in lymphocytes was significantly decreased.

• Authors: Johannes F Fahrmann, Oscar F Ballester, Gabriela Ballester, Theodore R Witte, Alexander J Salazar, Benjamin Kordusky, Kelsey G Cowen, Gabriela Ion, Donald A Primerano, Goran Boskovic, James Denvir, W Elaine Hardman
• Journal: Cancer investigation (Cancer Invest) Vol. 31 Issue 1 Pg. 24-38 (Jan 2013) ISSN: 1532-4192 [Electronic] England
• PMID: 23193970 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Fatty Acids, Omega-3
• NF-kappa B
• RNA, Messenger
• Doxorubicin

Topics

• Aged
• Aged, 80 and over
• Blood Platelets (drug effects, metabolism)
• Dietary Supplements
• Doxorubicin (therapeutic use)
• Fatty Acids, Omega-3 (administration & dosage, adverse effects, blood)
• Female
• Gene Expression Regulation, Neoplastic (drug effects)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (blood, drug therapy, genetics, metabolism)
• Lymphocytes (drug effects, metabolism)
• Male
• Middle Aged
• NF-kappa B (antagonists & inhibitors, genetics, metabolism)
• RNA, Messenger (genetics)